Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18885902 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18738959 | COMPOSITION FOR REGULATING PRODUCTION OF FUSION PROTEINS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18427711 | NON-TRANSGENE TRANSFECTION FOR THERAPEUTIC PURPOSES | January 2024 | June 2025 | Allow | 17 | 3 | 0 | Yes | No |
| 18474506 | Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use Thereof | September 2023 | July 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18275591 | TARGETED EXTRACELLULAR VESICLES FOR DELIVERY OF THERAPEUTICS | August 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18351689 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18351800 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18351674 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | July 2023 | November 2024 | Allow | 16 | 4 | 0 | Yes | No |
| 18322531 | METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF | May 2023 | January 2024 | Allow | 8 | 2 | 0 | No | No |
| 18316899 | VIRAL VECTORS FOR CANCER THERAPY | May 2023 | May 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18008674 | ARTIFICIAL NON-CODING RNA MODULE FOR ENHANCING NITROGEN FIXATION ABILITY OF MICROORGANISMS | December 2022 | January 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 17936023 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17843916 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | June 2022 | May 2024 | Abandon | 23 | 4 | 0 | No | No |
| 17540377 | Compositions and Methods for Treating Cancer with DuoCARs | December 2021 | March 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17498520 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17493032 | Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same | October 2021 | November 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17386063 | FABRY DISEASE GENE THERAPY | July 2021 | April 2025 | Allow | 44 | 2 | 0 | No | No |
| 17337018 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-BCMA IMMUNOTHERAPY | June 2021 | April 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17331733 | Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy | May 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17245952 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | April 2021 | December 2024 | Allow | 44 | 1 | 0 | No | No |
| 17206878 | Intrathecal Delivery of Recombinant Adeno-Associated Virus 9 | March 2021 | September 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17264911 | TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS | February 2021 | December 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 17150858 | METHODS FOR GENERATING ANIMALS WITH DESIRABLE TRAITS | January 2021 | February 2025 | Allow | 49 | 2 | 0 | No | No |
| 17139097 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | December 2020 | October 2024 | Abandon | 46 | 2 | 0 | No | No |
| 17124922 | Chimeric Growth Factor Receptors | December 2020 | June 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 17253491 | POLYNUCLEOTIDE | December 2020 | January 2025 | Abandon | 49 | 3 | 0 | No | No |
| 15733815 | USES AND METHODS FOR ONCOLYTIC VIRUS TARGETING OF IL-4/IL-13 AND FUSIONS THEREOF | November 2020 | April 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 17044085 | PRODUCTION OF BROWN ADIPOCYTES | September 2020 | June 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17040009 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | September 2020 | December 2024 | Allow | 51 | 2 | 1 | No | No |
| 17018088 | NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | September 2020 | October 2024 | Abandon | 49 | 2 | 0 | No | No |
| 17008086 | ARTIFICIAL ANTIGEN PRESENTING CELLS HAVING A DEFINED AND DYNAMIC SHAPE | August 2020 | June 2025 | Abandon | 58 | 3 | 0 | No | No |
| 16989307 | ALIGNED FIBER AND METHOD OF USE THEREOF | August 2020 | August 2024 | Allow | 48 | 2 | 0 | Yes | No |
| 16968602 | METHODS FOR SCREENING VARIANT OF TARGET GENE | August 2020 | January 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 16943335 | Altering Gene Expression in CART Cells and Uses Thereof | July 2020 | February 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 16965895 | USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | July 2020 | March 2025 | Allow | 55 | 2 | 0 | No | No |
| 16923606 | Electroporation Devices And Methods Of Cell Transfection | July 2020 | July 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16921783 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | July 2020 | May 2025 | Abandon | 59 | 4 | 0 | No | No |
| 16880402 | Controlled Transgene Expression in Regulatory T Cells | May 2020 | May 2024 | Allow | 48 | 4 | 1 | Yes | Yes |
| 16807254 | Collection, Genome Editing, And Washing Of T-Cell Lymphocytes | March 2020 | August 2024 | Allow | 53 | 3 | 0 | Yes | No |
| 16610883 | GENE THERAPY FOR CILIOPATHIES | November 2019 | July 2024 | Allow | 56 | 4 | 1 | Yes | No |
| 16498369 | SHRNA EXPRESSION CASSETTE, POLYNUCLEOTIDE SEQUENCE CARRYING SAME, AND APPLICATION THEREOF | September 2019 | December 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16537192 | NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY | August 2019 | July 2024 | Allow | 59 | 4 | 1 | Yes | Yes |
| 16502859 | MICROFLUIDIC DEVICES, SYSTEMS, INFRASTRUCTURES, USES THEREOF AND METHODS FOR GENETIC ENGINEERING USING SAME | July 2019 | March 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16409406 | COMPOSITIONS FOR THE INACTIVATION OF VIRUS REPLICATION AND METHODS OF MAKING AND USING THE SAME | May 2019 | May 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16405285 | ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER | May 2019 | June 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16326126 | METHODS AND COMPOSITIONS FOR TARGETED GENE TRANSFER | February 2019 | February 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16318965 | COMPOSITIONS AND METHODS FOR STUDYING THE TAT GENE | January 2019 | April 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16060651 | HUMAN T CELL DERIVED FROM T CELL-DERIVED INDUCED PLURIPOTENT STEM CELL AND METHODS OF MAKING AND USING | June 2018 | December 2024 | Allow | 60 | 9 | 1 | Yes | No |
| 15773779 | NUCLEIC ACIDS, PEPTIDES AND METHODS | May 2018 | April 2025 | Allow | 60 | 5 | 2 | Yes | No |
| 15571460 | COMPOSITIONS COMPRISING MESENCHYMAL STEM CELLS AND USES THEREOF | November 2017 | December 2024 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 15533983 | A Method for Producing a Recombinant Allotypespecific Rabbit Monoclonal Antibody | June 2017 | November 2024 | Allow | 60 | 5 | 1 | Yes | Yes |
| 15144637 | Oncolytic Adenoviruses for Cancer Treatment | May 2016 | March 2018 | Allow | 22 | 1 | 0 | No | No |
| 15137134 | METHODS OF DNA CONSTRUCTS FOR HIGH YIELD PRODUCTION OF POLYPEPTIDES | April 2016 | December 2017 | Allow | 19 | 1 | 0 | No | No |
| 15136726 | HYBRID CAULIMOVIRUS PROMOTERS AND CONSTRUCTS THEREOF | April 2016 | August 2017 | Allow | 16 | 2 | 0 | Yes | No |
| 14216907 | MODULATION OF MEIOTIC RECOMBINATION | March 2014 | October 2015 | Allow | 19 | 2 | 0 | No | No |
| 14073979 | Simian Adenovirus Nucleic Acid and Amino Acid Sequences, Vectors Containing Same, and Methods of Use | November 2013 | May 2015 | Allow | 18 | 1 | 1 | No | No |
| 13968757 | Simian Subfamily B Adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and Uses Thereof | August 2013 | July 2015 | Allow | 23 | 1 | 1 | No | No |
| 13930345 | CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF | June 2013 | December 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13930387 | CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF | June 2013 | April 2016 | Allow | 34 | 3 | 1 | No | No |
| 13930266 | CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF | June 2013 | December 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13930663 | Methods For Increasing Homologous Recombination Of A Nucleic Acid Sequence | June 2013 | June 2014 | Allow | 12 | 2 | 0 | No | No |
| 13930307 | CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF | June 2013 | January 2017 | Allow | 42 | 4 | 1 | No | No |
| 13751819 | DUPLEXED PARVOVIRUS VECTORS | January 2013 | March 2014 | Allow | 13 | 1 | 0 | No | No |
| 13729961 | USE OF A GRANULIN OR A GRANULIN-LIKE COMPOUND FOR THE THERAPY OR PROPHYLAXIS OF CHRONIC PAIN | December 2012 | January 2017 | Allow | 49 | 4 | 0 | Yes | Yes |
| 13710007 | METHODS FOR INCREASING HOMOLOGOUS RECOMBINATION OF A NUCLEIC ACID SEQUENCE | December 2012 | February 2013 | Allow | 2 | 0 | 0 | No | No |
| 13688864 | METHODS OF INHIBITING GROWTH OF A NEOPLASTIC CELL | November 2012 | April 2016 | Allow | 41 | 2 | 1 | Yes | No |
| 13434694 | METHODS FOR INCREASING HOMOLOGOUS RECOMBINATION OF A NUCLEIC ACID SEQUENCE | March 2012 | August 2012 | Allow | 5 | 0 | 0 | Yes | No |
| 13419189 | Transducible Polypeptides For Modifying Metabolism | March 2012 | August 2014 | Allow | 29 | 2 | 0 | No | No |
| 13399434 | NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES TO TARGET TISSUE | February 2012 | September 2014 | Allow | 31 | 3 | 0 | No | No |
| 13296878 | FACTOR TAKING PART IN TRANSCRIPTION CONTROL | November 2011 | July 2014 | Allow | 32 | 3 | 0 | Yes | No |
| 13225509 | CHIMERIC PROMOTERS CAPABLE OF MEDIATING GENE EXPRESSION IN PLANTS UPON PATHOGEN INFECTION AND USES THEREOF | September 2011 | July 2013 | Allow | 22 | 1 | 0 | No | No |
| 13112705 | METHODS AND COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES | August 2011 | May 2013 | Allow | 24 | 2 | 0 | No | Yes |
| 13171751 | NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES TO PLANTS | June 2011 | February 2013 | Allow | 20 | 1 | 1 | No | No |
| 13122339 | HCV ENTRY FACTOR, OCCLUDIN | June 2011 | October 2014 | Allow | 42 | 2 | 1 | Yes | No |
| 12597891 | PROMOTER INDUCIBLE BY REACTIVE OXYGEN SPECIES AND VECTOR COMPRISING THE SAME | June 2010 | May 2013 | Allow | 43 | 1 | 1 | Yes | No |
| 12817851 | Modified Viral Vector Particles | June 2010 | December 2013 | Allow | 42 | 2 | 1 | No | No |
| 12518967 | TOL1 FACTOR TRANSPOSASE AND DNA INTRODUCTION SYSTEM USING THE SAME | January 2010 | June 2013 | Allow | 48 | 1 | 1 | No | No |
| 11913106 | ANTIVIRAL RESISTANCE MUTANTS AND APPLICATIONS THEREOF | May 2008 | January 2013 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 12049862 | METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS MRNA-PROTEIN (MRNP) COMPLEXES | March 2008 | November 2011 | Allow | 44 | 2 | 0 | Yes | No |
| 11963207 | VARIANTS OF ALPHA-FETOPROTEIN CODING AND EXPRESSION SEQUENCES | December 2007 | November 2011 | Allow | 47 | 1 | 1 | No | No |
| 11932674 | NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES TO TARGET TISSUE | October 2007 | December 2011 | Allow | 49 | 2 | 1 | No | No |
| 11930892 | NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES TO PLANTS | October 2007 | July 2011 | Allow | 44 | 2 | 0 | Yes | No |
| 11977787 | COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE | October 2007 | September 2009 | Allow | 23 | 1 | 0 | Yes | No |
| 11854273 | Compositions and Methods for Regulating Peptidyltransferase Activity and Uses Thereof | September 2007 | July 2015 | Allow | 60 | 2 | 1 | Yes | Yes |
| 11820439 | SIMIAN ADENOVIRUS NUCLEIC ACID AND AMINO ACID SEQUENCES, VECTORS CONTAINING SAME, AND METHODS OF USE | June 2007 | September 2011 | Allow | 51 | 2 | 2 | No | No |
| 11542590 | ARTIFICIAL BIDIRECTIONAL PROMOTER FOR ACTIVATION OF GENE EXPRESSION | October 2006 | April 2008 | Allow | 18 | 2 | 0 | No | No |
| 10567661 | CHIMAERIC VECTOR SYSTEM | September 2006 | June 2012 | Allow | 60 | 5 | 1 | No | No |
| 11512563 | RHOB AS A SUPPRESSOR OF CANCER CELL GROWTH, CELL TRANSFORMATION, AND METASTASIS | August 2006 | August 2009 | Allow | 35 | 2 | 1 | Yes | No |
| 11453658 | ENHANCED MEDIATED DNA TRANSFER | June 2006 | February 2010 | Allow | 44 | 4 | 2 | No | No |
| 11442504 | TARGETED RETROGRADE GENE DELIVERY TO MOTOR NEURONS | May 2006 | October 2009 | Allow | 41 | 2 | 0 | Yes | No |
| 10559583 | Archaeon expression system | May 2006 | November 2013 | Allow | 60 | 5 | 0 | Yes | No |
| 11389432 | NONVIRAL VECTORS FOR DELIVERING POLYNUCLEOTIDES | March 2006 | June 2012 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 10571779 | METHOD FOR DETECTING MUTATION AND A METHOD FOR INDUCING MUTATION | March 2006 | August 2009 | Allow | 41 | 2 | 1 | No | No |
| 11023020 | DIRECTED APOPTOSIS IN COX-2 OVEREXPRESSING CANCER CELLS THROUGH EXPRESSION TARGETED GENE DELIVERY | December 2004 | August 2009 | Allow | 55 | 3 | 1 | No | No |
| 11003941 | Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same | December 2004 | January 2013 | Allow | 60 | 4 | 1 | Yes | Yes |
| 10999171 | METHODS FOR TARGETING RNA MOLECULES | November 2004 | April 2010 | Abandon | 60 | 6 | 1 | No | No |
| 10984406 | Regulatory sequences that direct gene expression to spinal motor neurons and uses thereof | November 2004 | May 2013 | Allow | 60 | 6 | 1 | Yes | Yes |
| 10972963 | METHODS AND COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES | October 2004 | May 2011 | Allow | 60 | 6 | 1 | Yes | No |
| 10489221 | CREATION OF ARTIFICIAL INTERNAL RIBOSOME ENTRY SITE (IRES) ELEMENTS | October 2004 | February 2012 | Allow | 60 | 4 | 1 | Yes | No |
| 10928815 | Rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method | August 2004 | April 2015 | Allow | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MARVICH, MARIA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MARVICH, MARIA works in Art Unit 1634 and has examined 142 patent applications in our dataset. With an allowance rate of 85.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 49 months.
Examiner MARVICH, MARIA's allowance rate of 85.9% places them in the 58% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MARVICH, MARIA receive 3.38 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MARVICH, MARIA is 49 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +6.5% benefit to allowance rate for applications examined by MARVICH, MARIA. This interview benefit is in the 34% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 45.9% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 82.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 28.9% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 11.5% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.